

Aug 11, 2025

Key Indices Update

Indices	Close	Change (%)
Nifty	24,363.30	0.95↓
Sensex	79,857.79	0.95↓
Midcap	56,002.20	1.64↓
Smallcap	17,428.20	1.49↓

Trend Strength Indicator

1553Nifty 50 Stocks above 200 EMA	NSE Advance / Decline
27	983/1966

Key Data

Data	Current	Previous
Dow Jones	44,317.0	44,085.5
U.S. Dollar Index	98.20	98.10
Brent Crude (USD/BBL)	66.10	66.45
US 10Y Bond Yield (%)	4.29	4.25
India 10Y Bond Yield (%)	6.38	6.37

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	54925.45	1.07↓
NIFTYAUTO	23461.95	1.45↓
NIFTYENERG	34357.25	0.74↓
NIFTYFINSR	28075.70	1.05↓
NIFTYFMCG	54893.10	0.73↓
NIFTYIT	34395.60	0.95↓
NIFTYMEDIA	1630.60	0.38↓
NIFTYMETAL	9141.80	1.81↓
NIFTYPHARM	21402.25	1.30↓
NIFTYREALT	872.35	2.31↓

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
ITC	FMCG	414	536	29.3%

*CMP as on August 08 2025

Top News

- ✦ **BEML Ltd.** has secured its **first international contract** in the **Rail & Metro sector** from **Malaysia**. The contract, valued at **USD 1 million**, involves the **Retrofit** and **Reconditioning** of the **Mass Rapid Transport (MRT) System**.
- ✦ **Sona Comstar** reported a **5% YoY decline in revenue** in Q1 FY26, while **EBITDA** fell by **19% YoY** and **Net Profit** decreased by **12% YoY**. During the quarter, the company's **BEV revenue** contracted by **25% YoY**, reflecting softness in the segment. In the same period, the **Net Order Book** expanded to **₹262 billion**, indicating a healthy future pipeline.

Technical

Refer Page 03-04

- ✦ **Nifty edged lower, failing to build on the previous session's rebound**, and ended with a loss of around one percent.
- ✦ After a flat start, the **Nifty gradually drifted downward and remained range-bound for most of the session**, before sharp selling in the final hour dragged it close to the day's low at 24,363 level.
- ✦ The medium-term moving average—the **100-day EMA**—near the **24,600 mark**, which earlier acted as support, is now serving as an immediate resistance.
- ✦ **A close below 24,450 signals the continuation of the corrective phase**, with a potential retest of the long-term moving average—the 200-day EMA—near 24,200.
- ✦ **Traders are advised to align their positions accordingly**, with greater emphasis on risk management.
- ✦ **Stock of the day - LIC**

Fundamental

Top News

01

BEML Ltd. has secured its **first international contract** in the **Rail & Metro sector** from **Malaysia**. The contract, valued at **USD 1 million**, involves the **Retrofit and Reconditioning** of the **Mass Rapid Transport (MRT) System**.

02

Sona Comstar reported a **5% YoY decline in revenue** in Q1 FY26, while **EBITDA** fell by **19% YoY** and **Net Profit** decreased by **12% YoY**. During the quarter, the company's **BEV revenue** contracted by **25% YoY**, reflecting softness in the segment. In the same period, the **Net Order Book** expanded to **₹262 billion**, indicating a healthy future pipeline.

03

Suprajit Engineering delivered **mixed performance** in Q1 FY26. **Consolidated revenue (excluding SCS)** grew by **5%**, while **standalone revenue** rose **3.5%**. **Consolidated EBITDA** recorded a **15% increase**, whereas **standalone EBITDA** declined by **6.5%**. During the quarter, the company also completed the **second tranche** of the **Stahlschmidt Cable Systems (SCS) acquisition**.

04

Happy Forgings reported Q1 FY26 result, with **revenue from operations** rising **3.6% YoY** to **₹354 crore** and **PAT** increasing **3.0% YoY** to **₹66 crore**. The growth was driven by strong momentum in the **passenger vehicles** and **industrial** segments. The company posted a **gross profit** of **₹205 crore** (up **6.3% YoY**) and **EBITDA** of **₹101 crore** (up **3.6% YoY**).

05

Shilpa Medicare announced the **CDSCO approval** of **Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg** in India for the treatment of **Non-Alcoholic Fatty Liver Disease (NAFLD)**. With this, **Shilpa becomes the first company globally** to launch this **novel product** for NAFLD, marking a **major milestone** in addressing a **significant unmet medical need**.

Stock for Investment

ITC Ltd.

Stock Symbol	ITC
Sector	FMCG
*CMP (₹)	414
^Target Price (₹)	536
Upside	29.3%

*CMP as on August 08, 2025

^Time horizon - upto 11 Months

- ✦ **ITC is a diversified FMCG company having strong presence in Cigarettes, Hotels, Paperboards and Packaging, Agri Business and Information Technology segments.**
- ✦ With a robust brand portfolio and **widespread market reach**, ITC effectively **mitigates risk through diversification**, capitalizing on brand equity to **capture market share** and **support sustained revenue**, thus reinforcing its leadership position.
- ✦ Company is **launching new products** across multiple categories and **expanding distribution**, ITC is strengthening its core businesses. With a robust brand portfolio and widespread market reach, ITC effectively mitigates risk through diversification, **capitalizing on brand equity to capture market share and support sustained revenue**, thus reinforcing its leadership position
- ✦ Overall, we expect **growth** to be **continuously driven by cigarettes, FMCG and Value added agri product segments.**
- ✦ On the financial front, we have estimated its revenue/ EBITDA/PAT to grow at 8.8%/11.1%/12.9% CAGR over FY25-27E and maintain **Buy rating** and a target price of **Rs 536**.

Technical

Negative tone to continue. Align positions accordingly.

NIFTY

24363.30 ▼ 232.85 (0.95%)

S1

24200

S2

24100

R1

24450

R2

24600

Technical Chart : Daily



- ✦ **Nifty edged lower, failing to build on the previous session's rebound, and ended with a loss of around one percent.**
- ✦ **The medium-term moving average—the 100-day EMA—near the 24,600 mark, which earlier acted as support, is now serving as an immediate resistance.**
- ✦ **A close below 24,450 signals the continuation of the corrective phase, with a potential retest of the long-term moving average—the 200-day EMA—near 24,200.**
- ✦ **Traders are advised to align their positions accordingly, with greater emphasis on risk management.**

BANKNIFTY

55004.90 ▼ 516.25 (0.93%)

S1

54500

S2

53900

R1

55300

R2

55600

Technical Chart : Daily



- ✦ **The banking index declined for the second consecutive week, exhibiting sustained bearish momentum.**
- ✦ **A bearish engulfing candlestick pattern on the daily chart signals further downside risk.**
- ✦ **All constituent stocks closed with negative bias, led predominantly by IndusInd Bank and Kotak Mahindra Bank.**
- ✦ **Critical support levels are identified between 54,300 and 53,900, while resistance is anticipated near 55,300 to 55,600.**

Technical

Stock of the day

LICI

Recom.

BUY

CMP (₹)

912.95

Range*

910-913

SL

885

Target

965

Technical Chart : Weekly



- ✦ **LICI opened with a bullish gap-up** and sustained upward momentum, **surpassing the two-week high**.
- ✦ **The 100-day EMA provides strong technical support**, reinforced by rising volume, indicating short-term bullish sentiment.
- ✦ **On the weekly chart, the primary trend remains positive**, with the stock completing a 38.2% Fibonacci retracement of the March 3 to June 30 rally.
- ✦ **Investors may consider initiating long positions** within the current support zone.

Momentum Stocks Midcap

Name	Price	Price %
KRBL	419.30	12.76↗
GSFC	211.85	6.49↗
MEDANTA	1408.70	6.16↗
VIPIND	426.00	5.35↘
KALYANKJIL	532.00	9.98↘

Name	Price	Price %
TITAGARH	801.50	6.14↘
COFORGE	1606.90	5.70↘
MAZDOCK	2634.90	5.39↘
ANGELONE	2552.00	3.41↘
ASHOKLEY	115.90	3.26↘

Range Breakout/ Breakdown

Top 5 F&O Gainers ↗

Name	Price	Price %
IEX	138.04	3.43↗
CUMMINSIND	3791.00	3.18↗
BPCL	319.80	3.04↗
LICI	910.80	2.92↗
MFSL	1545.00	2.66↗

Name	Price	Price %
PGEL	567.35	23.00↘
KALYANKJIL	531.85	10.00↘
JSL	679.90	6.17↘
BIOCON	341.75	6.16↘
TITAGARH	801.50	6.14↘

Top 5 F&O Losers ↘

Bullish Charts

Name	Price	Price %
CUMMINSIND	3791.00	3.18↗
FORTIS	897.35	1.51↗
HDFCLIFE	759.80	0.54↗
PIDILITIND	3074.00	0.76↗
TITAN	3466.70	1.49↗

Name	Price	Price %
AMBER	7300.00	5.56↘
COFORGE	1606.90	5.70↘
DIXON	15816.00	5.08↘
MAZDOCK	2634.90	5.39↘
PGEL	567.35	23.00↘

Bearish Charts

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Vinay Kalani</i>	vinay.kalani1@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

